Sage sacks staff as FDA miss makes slower growth more likely

1 September 2023
sage-large

Reeling from a  regulatory setback last month, Sage Therapeutics (Nasdaq: SAGE) is to undergo a major restructuring in the run-up to its launch of postpartum depression drug Zurzuvae (zuranolone).

The East Coast, USA-based company secured approval for Zurzuvae for adults with postpartum depression (PPD) last month, but missed out on the much larger indication of major depressive disorder (MDD).

Analysts have forecast that approval in MDD could make Zurzuvae a future blockbuster product, while PPD is expected to lead to up to half a billion dollars in peak revenues.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical